Recent Developments in Myelodysplastic Syndromes / / edited by Ota Fuchs.
This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patie...
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | [Place of publication not identified] : : IntechOpen,, 2019. |
Year of Publication: | 2019 |
Language: | English |
Physical Description: | 1 online resource (120 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546196304498 |
---|---|
ctrlnum |
(CKB)4970000000100472 (NjHacI)994970000000100472 (oapen)https://directory.doabooks.org/handle/20.500.12854/57767 (EXLCZ)994970000000100472 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ota Fuchs auth Recent Developments in Myelodysplastic Syndromes / edited by Ota Fuchs. IntechOpen 2019 [Place of publication not identified] : IntechOpen, 2019. 1 online resource (120 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (InTech, viewed October 17, 2022). Includes bibliographical references and index. This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patients with MDS have myeloid dysplasia, intramedullary apoptosis and an increased risk of transformation to acute myeloid leukemia (AML). The use of next generation sequencing has allowed for the identification of molecular mutations in several genes in about 90% of MDS patients. Several mutations will likely be incorporated into future prognostic scoring systems for MDS. About 50% of MDS cases are characterized by the presence of cytogenetic abnormalities. The correct morphological and cytogenetic analysis interpretation plays an important role in diagnosis and prognosis of these disorders. Cell death and an inflammatory gene signature are associated with MDS. Better understanding of the genetic and molecular mechanisms of MDS pathogenesis provides an opportunity for new treatment strategies to be developed. Promising novel therapies targeting pathophysiological mechanisms of MDS are being studied but the drugs currently used in MDS therapy remain limited. The only curative therapy for MDS is allogeneic hematopoietic stem cell transplantation. Recent advances in strategies to minimize transplant-related toxicity make this treatment possible for more MDS patients who are sufficiently fit. English Myelodysplastic syndromes. Medicine Hematological Oncology Hematology Health Sciences 1-78985-477-6 Fuchs, Ota, editor. |
language |
English |
format |
eBook |
author |
Ota Fuchs |
spellingShingle |
Ota Fuchs Recent Developments in Myelodysplastic Syndromes / |
author_facet |
Ota Fuchs Fuchs, Ota, |
author_variant |
o f of |
author2 |
Fuchs, Ota, |
author2_variant |
o f of |
author2_role |
TeilnehmendeR |
author_sort |
Ota Fuchs |
title |
Recent Developments in Myelodysplastic Syndromes / |
title_full |
Recent Developments in Myelodysplastic Syndromes / edited by Ota Fuchs. |
title_fullStr |
Recent Developments in Myelodysplastic Syndromes / edited by Ota Fuchs. |
title_full_unstemmed |
Recent Developments in Myelodysplastic Syndromes / edited by Ota Fuchs. |
title_auth |
Recent Developments in Myelodysplastic Syndromes / |
title_new |
Recent Developments in Myelodysplastic Syndromes / |
title_sort |
recent developments in myelodysplastic syndromes / |
publisher |
IntechOpen IntechOpen, |
publishDate |
2019 |
physical |
1 online resource (120 pages) |
isbn |
1-83962-040-4 1-78985-478-4 1-78985-477-6 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC645 |
callnumber-sort |
RC 3645.73 R434 42019 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.41 |
dewey-sort |
3616.41 |
dewey-raw |
616.41 |
dewey-search |
616.41 |
work_keys_str_mv |
AT otafuchs recentdevelopmentsinmyelodysplasticsyndromes AT fuchsota recentdevelopmentsinmyelodysplasticsyndromes |
status_str |
n |
ids_txt_mv |
(CKB)4970000000100472 (NjHacI)994970000000100472 (oapen)https://directory.doabooks.org/handle/20.500.12854/57767 (EXLCZ)994970000000100472 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Recent Developments in Myelodysplastic Syndromes / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796648787202015232 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01051nam a2200301 i 4500</leader><controlfield tag="001">993546196304498</controlfield><controlfield tag="005">20221017195918.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">221017s2019 xx ob 001 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1-83962-040-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1-78985-478-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4970000000100472</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994970000000100472</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/57767</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994970000000100472</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC645.73</subfield><subfield code="b">.R434 2019</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.41</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ota Fuchs</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Recent Developments in Myelodysplastic Syndromes /</subfield><subfield code="c">edited by Ota Fuchs.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">IntechOpen</subfield><subfield code="c">2019</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">IntechOpen,</subfield><subfield code="c">2019.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (120 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (InTech, viewed October 17, 2022).</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patients with MDS have myeloid dysplasia, intramedullary apoptosis and an increased risk of transformation to acute myeloid leukemia (AML). The use of next generation sequencing has allowed for the identification of molecular mutations in several genes in about 90% of MDS patients. Several mutations will likely be incorporated into future prognostic scoring systems for MDS. About 50% of MDS cases are characterized by the presence of cytogenetic abnormalities. The correct morphological and cytogenetic analysis interpretation plays an important role in diagnosis and prognosis of these disorders. Cell death and an inflammatory gene signature are associated with MDS. Better understanding of the genetic and molecular mechanisms of MDS pathogenesis provides an opportunity for new treatment strategies to be developed. Promising novel therapies targeting pathophysiological mechanisms of MDS are being studied but the drugs currently used in MDS therapy remain limited. The only curative therapy for MDS is allogeneic hematopoietic stem cell transplantation. Recent advances in strategies to minimize transplant-related toxicity make this treatment possible for more MDS patients who are sufficiently fit.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Myelodysplastic syndromes.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hematological Oncology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hematology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Health Sciences</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">1-78985-477-6</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuchs, Ota,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 20:28:46 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-04-13 22:04:18 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5351681670004498&Force_direct=true</subfield><subfield code="Z">5351681670004498</subfield><subfield code="b">Available</subfield><subfield code="8">5351681670004498</subfield></datafield></record></collection> |